Skip to main content
  • Main menu
  • User menu
  • Search
  • English ▼
    • English
    • Afrikaans
    • Albanian
    • Amharic
    • Arabic
    • Armenian
    • Azerbaijani
    • Basque
    • Belarusian
    • Bengali
    • Bosnian
    • Bulgarian
    • Catalan
    • Cebuano
    • Chichewa
    • Chinese (Simplified)
    • Chinese (Traditional)
    • Corsican
    • Croatian
    • Czech
    • Danish
    • Dutch
    • Esperanto
    • Estonian
    • Filipino
    • Finnish
    • French
    • Frisian
    • Galician
    • Georgian
    • German
    • Greek
    • Gujarati
    • Haitian Creole
    • Hausa
    • Hawaiian
    • Hebrew
    • Hindi
    • Hmong
    • Hungarian
    • Icelandic
    • Igbo
    • Indonesian
    • Irish
    • Italian
    • Japanese
    • Javanese
    • Kannada
    • Kazakh
    • Khmer
    • Korean
    • Kurdish (Kurmanji)
    • Kyrgyz
    • Lao
    • Latin
    • Latvian
    • Lithuanian
    • Luxembourgish
    • Macedonian
    • Malagasy
    • Malay
    • Malayalam
    • Maltese
    • Maori
    • Marathi
    • Mongolian
    • Myanmar (Burmese)
    • Nepali
    • Norwegian
    • Pashto
    • Persian
    • Polish
    • Portuguese
    • Punjabi
    • Romanian
    • Russian
    • Samoan
    • Scottish Gaelic
    • Serbian
    • Sesotho
    • Shona
    • Sindhi
    • Sinhala
    • Slovak
    • Slovenian
    • Somali
    • Spanish
    • Sudanese
    • Swahili
    • Swedish
    • Tajik
    • Tamil
    • Telugu
    • Thai
    • Turkish
    • Ukrainian
    • Urdu
    • Uzbek
    • Vietnamese
    • Welsh
    • Xhosa
    • Yiddish
    • Yoruba
    • Zulu

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

English ▼
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scottish Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sudanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
NewsSNMMI Newsline

68Ga-PSMA Ligand as Potential 99mTc-DMSA Alternative

Ismet Sarikaya
Journal of Nuclear Medicine November 2019, 60 (11) 12N;
Ismet Sarikaya
Kuwait University Faculty of Medicine Mubarak Al-Kabeer Hospital Kuwait City, Kuwait
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Newsline Editor: I read with great interest the paper by Lim et al. (1) that was published in the August issue of JNM Newsline. The article highlighted the importance of 99mTc-dimercaptosuccinic acid (99mTc-DMSA) scans in pyelonephritis and other renal cortical diseases and the implications of current shortages of 99mTc DMSA in the United States. We have recently published 68Ga–prostate-specific membrane antigen (68Ga-PSMA) ligand PET/CT images of the kidneys that show a high degree of uptake and excellent distribution of this radiotracer in the renal cortex and demonstrate renal parenchymal defects caused by various sizes of renal cysts (2,3). 68Ga-PSMA ligand renal images appear to be superior to those acquired with 99mTc-DMSA (2,3).

The main limitations of DMSA scanning include the relatively long waiting time after radiotracer injection, long acquisition time, high radiation dose (particularly important in repeated studies in children), and limited spatial resolution with gamma cameras. 68Ga has a shorter half-life (68 min) than 99mTc (6 h). Effective and kidney radiation doses with the 68Ga-PSMA ligand appear to be comparable to those with 99mTc-DMSA, but this should be further studied (4–6). The CT component of PET/CT imaging further increases radiation dose, but CT images may not be needed because non–attenuation-corrected PET also provides good quality images of the kidneys as a result of high renal cortical uptake. This is particularly important when used in pediatric patients (2,3). Waiting time after radiotracer injection and image acquisition time is less with 68Ga-PSMA ligand PET (30–60 min and 2–6 min, respectively) than for the DMSA scan (2–3 h and 15–30 min, respectively). PET scanners offer higher efficiency for detecting gamma photons and higher spatial resolution than gamma cameras (7).

Although the 68Ga-PSMA ligand is more expensive than 99mTc-DMSA and not available at every institute, it would be worthwhile to directly compare PSMA PET to DMSA scanning in renal diseases to better understand whether this PET radiotracer could be used to image the renal cortex and serve as an alternative to DMSA scanning, particularly in countries with shortages of 99mTc-DMSA. We have recently received institutional approval for a prospective research project for such a comparison in adult patients with pyelonephritis, and the study will begin soon.

  • © 2019 by the Society of Nuclear Medicine and Molecular Imaging.

References

  1. 1.↵
    1. Lim R,
    2. Bar-Sever Z,
    3. Treves ST
    . Is availability of 99mTc-DMSA insufficient to meet clinical needs in the United States? A survey. J Nucl Med. 2019;60[8]:14N–16N.
    OpenUrlFREE Full TextGoogle Scholar
  2. 2.↵
    1. Sarikaya I,
    2. Elgazzar AH,
    3. Alfeeli MA,
    4. Sarikaya A
    . Can gallium-68 prostate-specific membrane antigen ligand be a potential radiotracer for renal cortical positron emission tomography imaging? World J Nucl Med. 2018;17:126–129.
    OpenUrlGoogle Scholar
  3. 3.↵
    1. Sarikaya I,
    2. Sarikaya A
    . Current status of radionuclide renal cortical imaging in pyelonephritis. J Nucl Med Technol. 2019 Jun 10. E-published ahead of print.
    Google Scholar
  4. 4.↵
    1. Mandell GA,
    2. Eggli DF,
    3. Gilday DL,
    4. et al
    . Procedure Guideline for Renal Cortical Scintigraphy in Children. Society of Nuclear Medicine. J Nucl Med. 1997;38:1644–1646.
    OpenUrlFREE Full TextGoogle Scholar
  5. 5.
    1. Fendler WP,
    2. Eiber M,
    3. Beheshti M,
    4. et al
    . 68Ga-PSMA PET/CT: Joint EANM and SNMMI Procedure Guideline for Prostate Cancer Imaging: Version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014–1024.
    OpenUrlGoogle Scholar
  6. 6.↵
    1. Afshar-Oromieh A,
    2. Hetzheim H,
    3. Kübler W,
    4. et al
    . Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611–1620.
    OpenUrlCrossRefPubMedGoogle Scholar
  7. 7.↵
    1. Daghighian F,
    2. Sumida R,
    3. Phelps ME
    . PET imaging: An overview and instrumentation. J Nucl Med Technol. 1990;18:5–13.
    OpenUrlAbstract/FREE Full TextGoogle Scholar
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 60 (11)
Journal of Nuclear Medicine
Vol. 60, Issue 11
November 1, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Share
68Ga-PSMA Ligand as Potential 99mTc-DMSA Alternative
Ismet Sarikaya
Journal of Nuclear Medicine Nov 2019, 60 (11) 12N;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
Bookmark this article

Jump to section

  • Article
    • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Renal Cortical 68Ga-PSMA-11 PET and 99mTc-DMSA Images
  • Google Scholar

More in this TOC Section

  • 2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 1
  • SNMMI Newsline
  • From the Literature
Show more SNMMI Newsline

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire
Alerts for this Article
Sign In to Email Alerts with your Email Address
Email this Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
68Ga-PSMA Ligand as Potential 99mTc-DMSA Alternative
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
68Ga-PSMA Ligand as Potential 99mTc-DMSA Alternative
Ismet Sarikaya
Journal of Nuclear Medicine Nov 2019, 60 (11) 12N;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

We use cookies on this site to enhance your user experience

By clicking any link on this page you are giving your consent for us to set cookies.